Magnesium ions and opioid agonist activity in streptozotocin-induced hyperalgesia

Pharmacology

Volumn 82, Issue 3, 2008, Pages 180-186

  Bujalska, Magdalena ^a   Malinowska, Ewelina ^a   Makulska Nowak, Helena ^a   Gumułka, Stanisław Witold ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Buprenorphine; Diabetes; Fentanyl; Hyperalgesia; Magnesium ions; Morphine; Rats; Streptozotocin

Indexed keywords

BUPRENORPHINE; FENTANYL; MAGNESIUM ION; MAGNESIUM SULFATE; MORPHINE; OPIATE AGONIST; STREPTOZOCIN;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG POTENTIATION; HYPERALGESIA; MALE; MONOTHERAPY; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FENTANYL; HYPERALGESIA; INJECTIONS, INTRAPERITONEAL; MAGNESIUM SULFATE; MALE; MORPHINE; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 49149087151     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151346     Document Type: Article

References (32)

1. Dyck PJ, Dyck PJ, Larson TS, O'Brien PC, Velosa JA: Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 2000;23:510-517.
2. Dobretsov M, Hastings SL, Romanovsky D, Stimers JR, Zhang JM: Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res 2003;960:174-183.
3. Romanovsky D, Hastings SL, Stimers JR, Dobretsov M: Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. J Peripher Nerv Syst 2004;9:62-69.
4. Gabra BH, Benrezzak O, Pheng LH, Duta D, Daull P, Sirois P, Nantel F, Battistini B: Inhibition of type 1 diabetic hyperalgesia in streptozotocin- induced Wistar versus spontaneous gene-prone BB/Worchester rats: efficacy of a selective bradykinin B1 receptor antagonist. J Neuropathol Exp Neurol 2005;64:782-789.
5. Nakhoda A, Wong HA: The induction of diabetes in rats by intramuscular administration of streptozotocin. Experientia 1979;35:1679-1980.
6. Randall LO, Selitto JJ: A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-419.
7. Tallarida RJ, Murray RB: Manual of Pharmacologic Calculation with Computer Programs, ed 2. New York, Springer, 1986, pp 113-117.
8. Clark CM Jr, Lee DA: Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995;332:1210-1217.
9. Aley KO, Levine JD: Different peripheral mechanisms mediate enhanced nociception in metabolic/toxic and traumatic painful peripheral neuropathies in the rat. Neuroscience 2002;111:389-397.
10. Dellemijn P: Are opioids effective in relieving neuropathic pain? Pain 1999;80:453-462.
11. Kamei J, Ohhashi Y, Aoki T, Kawasima N, Kasuya Y: Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not delta-and kappa-opioid agonists. Brain Res 1992;571:199-203.
12. Courteix C, Bardin M, Chantelauze C, Laverenne J, Eschalier A: Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994;57:153-160.
13. Zurek JR, Nadeson R, Goodchild CS: Spinal and supraspinal components of opioid antinociception in streptozotocin-induced diabetes neuropathy in rats. Pain 2001;90:57-63.
14. Raz I, Hasdai D, Seltzer Z, Melmed RN: Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. Diabetes 1998;37:1253-1259.
15. Ulugol A, Aslantas A, Ipci Y, Tuncer A, Karadag CH, Dokmeci I: Combined systemic administration of morphine and magnesium sulfate attenuates pain-related behavior in mononeuropathic rats. Brain Res 2002;943:101-104.
16. Bordi F, Quartaroli M: Modulation of nociceptive transmission by NMDA/glycine site receptor in the ventroposterolateral nucleus of the thalamus. Pain 2000;84:213-224.
17. Parsons CG: NMDA receptors as targets for drug action in naturopathic pain. Eur J Pharmacol 2001;429:71-78.
18. Dickenson AH: NMDA receptor antagonists: interactions with opioids. Acta Anaesthesiol Scan 1997;41:112-115.
19. Malyshkin AA, Medvedev IO, Danysz W, Bespalov AY: Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine neuropathic rats. Eur J Pharmacol 2005;519:80-85.
20. Christensen D, Gautron M, Guilbaud G, Kayser V: Combined systemic administration of the glycine/NMDA receptor antagonist, (+)-HA966 and morphine attenuates pain-related behaviour in a rat of trigeminal neuropathic pain. Pain 1999;83:433-440.
21. Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H: Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol 1998;56:553-559.
22. Mao J, Donald D, Mayer P, Mayer DJ: Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995;61:353-364.
23. Yamamoto T, Yaksh TL: Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 1992;135:67-70.
24. Nicholas ML, Lopez Y, Ossipov MH, Bian D, Porreca F: Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A or MK-801 in a nerve-ligation model of peripheral neuropathy. Pain 1997;69:317-322.
25. Yamakura T, Sakimura K, Shimoji K: Direct inhibition of the N-methyl-D-aspartate receptor channel by high concentrations of opioids. Anesthesiology 1999;91:1053-1063.
26. Bolcal C, Iyem H, Sargin M, Mataraci I, Yildirim V, Doganci S, Ozal E, Demirkilic U, Tatar H: Comparison of magnesium sulfate with opioid and NSAIDs on postoperative pain management after coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2005;19:714-718.
27. Begon S, Pickering G, Eschalier A: Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology 2002;96:627-632.
28. Crosby V, Wilcock A, Corcoran R: The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. J Pain Symptom Manage 2000;19:35-39.
29. Tramer MR, Schneider J, Marti RA, Rifat K: Role magnesium sulfate in postoperative analgesia. Anesthesiology 1996;84:340-347.
30. McCarthy RJ, Kroin JS, Tuman KJ, Penn RD, Ivankovich AD: Antinociceptive potentiation and attenuation of tolerance by intrathecal co-infusion of magnesium sulfate and morphine in rats. Anesth Analg 1998;86:830-836.
31. Özalevli M, Cetin TO, Unlugenc H, Guler T, Isik G: The effect of adding intrathecal magnesium sulphate to bupivacaine-fentanyl spinal anaesthesia. Acta Anaesthesiol Scand 2005;49:1514-1519.
32. Buvanendran A, McCarthy RJ, Kroin JS, Leong W, Perry P, Tuman KJ: Intrathecal magnesium prolongs fentanyl analgesia: a prospective, randomized, controlled trial. Anesth Analg 2002;95:661-666.